DICE Therapeutics, Inc. - Common Stock (NQ:DICE)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 8, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about DICE Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

September 01, 2023

Via Investor Brand Network

Why These 3 Large Caps Are Bucking the August Slump

August 22, 2023

The three largest S&P 500 outperformers of August are tacking on gains in a weak market, making them intriguing momentum plays to watch for the rest of 2023.

Via MarketBeat

Topics Economy Stocks

What 9 Analyst Ratings Have To Say About DICE Therapeutics ↗

August 09, 2023

Via Benzinga

Analyst Expectations for DICE Therapeutics's Future ↗

June 20, 2023

Via Benzinga

Health Care Company Eli Lilly Announces Acquisition of DICE Therapeutics ↗

June 20, 2023

Via Benzinga

Top 5 Health Care Stocks That May Crash In Q3 ↗

August 07, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Eli Lilly To Report Q2 Earnings: What's In The Cards? ↗

August 05, 2023

Eli Lilly & Company will report second-quarter 2023 results on Aug. 8, before the market opens.

Via Talk Markets

M&A Activity, Booming Sales of Anti-IL-17 Drugs Suggest Strong Upside Potential for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

July 26, 2023

Via Investor Brand Network

Topics Intellectual Property

MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022 ↗

July 17, 2023

MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for...

Via Benzinga

DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE

July 10, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Why Shares of Ventyx Biosciences Rose Monday ↗

July 03, 2023

The company has several promising autoimmune therapies.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023 ↗

June 26, 2023

Via Benzinga

Stock Market Pulls Back After Several Weeks Of Gains: Weekly Review ↗

June 23, 2023

But the major indexes and leading stocks generally showed healthy action.

Via Investor's Business Daily

Why Dice Therapeutics Stock Bolted Higher This Week ↗

June 22, 2023

The small-cap drugmaker fetched a hefty premium in a buyout deal with Eli Lilly.

Via The Motley Fool

Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event? ↗

June 21, 2023

The pharma giant's latest acquisition might be on the small side, but it could yield an important new growth driver in the years ahead.

Via The Motley Fool

DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE

June 21, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2023 ↗

June 21, 2023

Via Benzinga

Red Hot Eli Lilly Rolls the DICE With Its Latest Biotech Takeover

June 21, 2023

The market’s initial positive reaction to the DICE Therapeutics news suggests Eli Lilly shares will continue to sizzle this summer.

Via MarketBeat

Eli Lilly's $2.4 Billion Acquisition of Dice Therapeutics: What Investors Need to Know ↗

June 20, 2023

Lilly could get a couple of promising autoimmune-disease drugs with the transaction.

Via The Motley Fool

Crude Oil Down 2%; Dragonfly Energy Shares Plunge ↗

June 20, 2023

U.S. stocks traded lower toward the end of trading, with Dow Jones dropping over 150 points on Tuesday. The Dow traded down 0.50% to 34,129.29while the NASDAQ fell 0.16% to 13,668.76 The S&P 500, also...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

June 20, 2023

Via Benzinga

Dow Dips Over 300 Points; DICE Therapeutics Shares Spike Higher ↗

June 20, 2023

U.S. stocks traded lower midway through trading, with Dow Jones dropping over 300 points on Tuesday. The Dow traded down 0.96% to 33,969.42 while the NASDAQ fell 0.74% to 13,588.13. The S&P 500, also...

Via Benzinga

Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 20, 2023

Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.

Via Benzinga

Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments

June 20, 2023

Via Spotlight Growth

Why Shares of Dice Therapeutics Are Skyrocketing Tuesday ↗

June 20, 2023

The company received a buyout offer from Eli Lilly.

Via The Motley Fool

PLTR Stock Alert: Why Raymond James Just Downgraded Palantir ↗

June 20, 2023

Palantir (PLTR) stock is on the move Tuesday after Raymond James analysts downgraded the company's shares but increased its price target.

Via InvestorPlace

DICE Therapeutics, Surmodics, Nikola, And Other Big Stocks Moving Higher On Tuesday ↗

June 20, 2023

U.S. stocks traded lower, with the Dow Jones dropping around 250 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

RIVN Stock Alert: Rivian Jumps on the Tesla Bandwagon for EV Charging ↗

June 20, 2023

Rivian (RIVN) stock is in the news Tuesday as investors react to the electric vehicle (EV) company joining Tesla's (TSLA) charging standard.

Via InvestorPlace

US Stocks Mixed; Housing Starts Surge In May ↗

June 20, 2023

U.S. stocks traded mixed this morning, with Dow Jones dropping over 150 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.52% to 34,120.19 while the NASDAQ rose 0.15% to...

Via Benzinga

Eli Lilly To Acquire Small Company DICE Therapeutics Focused On Autoimmune Diseases For $2B ↗

June 20, 2023

Eli Lilly And Co (NYSE: LLY) has agreed to acquire DICE Therapeutics Inc (NASDAQ: DICE), a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop oral...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.